Trial Profile
A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks With a 12 Week Follow up Period in Patients With Nonproliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema (ROBIN Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs BI 1467335 (Primary)
- Indications Diabetic retinopathy
- Focus Adverse reactions
- Acronyms ROBIN Study
- Sponsors Boehringer Ingelheim
- 07 Sep 2020 According to a Boehringer Ingelheim Media Release, the company decided not to further develop BI 1467335 in this indication based on the lack of a clear efficacy signal and risk of dose dependent drug interactions of the compound in NPDR patients identified in another Phase I study.
- 07 Sep 2020 Results presented in the Boehringer Ingelheim Media Release.
- 22 May 2020 Status changed from active, no longer recruiting to completed.